Journal
ONCOTARGET
Volume 6, Issue 29, Pages 27714-27724Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4663
Keywords
multiple myeloma; cancer stem cells; paclitaxel; nanoparticles; ATP-binding cassette sub-family G member 2
Categories
Funding
- 973 National Nature Science Foundation of People's Republic of China [2011CB933500]
- Graduate Student Research and Innovation Program of Jiangsu Province [CXZZ-0174]
- National Natural Science Foundation of China [81001412, 61127002, 61179035]
Ask authors/readers for more resources
Multiple myeloma (MM) remains to be an incurable disease. The purpose of this study was to evaluate the effect of ABCG2 monoclonal antibody (McAb) combined with paclitaxel (PTX) conjugated with Fe3O4 nanoparticles (NPs) on MM progressed from cancer stem cells (CSCs) in non-obese-diabetic/severe-combined-immunodeficiency (NOD/SCID) mouse model. Mice were injected with MM CSCs as marked by CD138(-)CD34(-) phenotypes through tail veins. The developed MM mice were examined by micro-computer tomography scanning, ultrasonography and enzyme-linked immunosorbent analysis. These mice were then intravenously treated with different combinations of NPs, PTX, McAb, PTX-NPs and melphalan/prednisone once a week for four weeks. The injected mice developed characteristic MM-associated syndromes, including lytic bone lesions, renal damages and proteinuria. All the treated mice showed decrease in bone lesions, renal damages and anemia but increase in apoptosis compared with the mice treated with NPs only. In particular, the treatment with ABCG2 McAb plus PTX-NPs induced the strongest therapeutic response and had an efficacy even better than that of melphalan/prednisone, a conventional regimen for MM patients. These data suggest that PTX-NPs with ABCG2 McAb can be developed into potential treatment regimens for patients with relapsed/refractory MM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available